Ziopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Ziopharm’s Board of Directors

    NEXT STORY
    Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
    PREV STORY
    The Global Immunoprotein Diagnostic Testing Market is expected to grow by $ 5.56 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017

    WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its ...

    author_avatar
    NASDAQ Market News

    BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial

    author_avatar
    NASDAQ Market News

    Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018

    THE WOODLANDS, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced ...

    author_avatar
    NASDAQ Market News